Home Acta Virologica 2021 Acta Virologica Vol.65, No.1, p.82-88, 2021

Journal info


Quarterly,
Founded: 1957
ISSN 0001-723X
E-ISSN 1336-2305

Published in English

Aims and Scope
Editorial Info

Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Acta Virologica Vol.65, No.1, p.82-88, 2021

Title: Optimization of a cellular HBV infection model for use in high-throughput drug screening
Author: Nadezhda P. Kartashova, Svetlana I. Iarovenko, Ekaterina A. Glubokova, Ilya A. Potemkin, Anastasia A. Karlsen, Irina A. Leneva, Karen K. Kyuregyan, Alexey A. Ryakhovskiy, Mikhail I. Mikhailov

Abstract: Hepatitis B virus (HBV) is a partially double-stranded DNA virus that specifically targets hepatocytes. It is considered a major health issue due to its high prevalence and the life-threatening consequences of chronic infection, including liver cirrhosis and hepatocellular carcinoma. Despite widespread vaccination against HBV, millions of people live with chronic HBV infection. Existing antiviral therapies fail to achieve full HBV elimination, so most patients with the disease require lifelong treatment. The search for new antiviral therapy strategies is hindered by the limited availability of in vitro HBV infection models that are able to support the full HBV life cycle. Therefore, the development and optimization of cellular models are crucial to the search for drugs effective against HBV. In this study, we optimized an in vitro HBV infection model consisting of two cell lines: HepAD38 cells, which are able to produce infectious HBV; and HepG2-NTCP cells, which are susceptible to HBV infection. We showed that prolonged production of HBV in the “donor” cells and HBV inoculation of the “acceptor” cells simultaneously with seeding improves the established procedure. This modified protocol was proven effective in experiments involving compounds with known activity against HBV, suggesting its utility for future high-throughput screening.

Keywords: HBV; HBV in vitro models; HepG2-NTCP; HepAD38
Published online: 23-Feb-2021
Year: 2021, Volume: 65, Issue: 1 Page From: 82, Page To: 88
doi:10.4149/av_2021_110
Price: 16.80 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.